Connaught/Pasteur-Merieux' ALVAC-HIV canarypox AIDS vaccine to enter new NIAID AVEG trials.
CONNAUGHT/PASTER-MERIEUX' ALVAC-HIV AIDS VACCINE IS ONE OF THREE investigational AIDS vaccines beginning clinical trials under the auspices of the National Institute of Allergy & Infectious Disease AIDS Vaccine Evaluation Group, NIAID announced June 13. ALVAC-HIV (vCP205) is a live recombinant vaccine made from a weakened canarypox virus that may be safer than previous cowpox virus vaccines because it "does not grow in human cells," NIAID said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth